Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation.
Schwartz
Neil E
NE
Stanford Stroke Center, Department of Neurology & Neurological Sciences, Stanford University, Palo Alto, CA, USA. neuro1@stanford.edu
Albers
Gregory W
GW
D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000069604:Dabigatran; D006801:Humans; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000627:therapeutic use*; D020521:Stroke / Q000209:etiology* / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D001562:Benzimidazoles; D011725:Pyridines; D014859:Warfarin; D000069604:Dabigatran